184 related articles for article (PubMed ID: 35680632)
1. [Analysis of the effect of gene mutations on the efficacy of ruxolitinib in patients with myelofibrosis based on second-generation sequencing technology].
Tan YX; Luo J; Huang JX; Luo DM; Liang HY; Zhou X; Liu XL; Xu N
Zhonghua Xue Ye Xue Za Zhi; 2022 Apr; 43(4):323-329. PubMed ID: 35680632
[No Abstract] [Full Text] [Related]
2. Clinical efficacy and safety of ruxolitinib in the management of myelofibrosis: A single institution experience in Taiwan.
Chen YY; Huang CE; Lee KD; Chen CC
Hematology; 2016 Jan; 21(1):3-9. PubMed ID: 26214121
[TBL] [Abstract][Full Text] [Related]
3. Ruxolitinib in elderly patients with myelofibrosis: impact of age and genotype. A multicentre study on 291 elderly patients.
Palandri F; Catani L; Bonifacio M; Benevolo G; Heidel F; Palumbo GA; Crugnola M; Abruzzese E; Bartoletti D; Polverelli N; Bergamaschi M; Tiribelli M; Iurlo A; Breccia M; Cavazzini F; Tieghi A; Binotto G; Isidori A; Martino B; D'Adda M; Bosi C; Sabattini E; Vitolo U; Aversa F; Ibatici A; Lemoli RM; Sgherza N; Cuneo A; Martinelli G; Semenzato G; Cavo M; Vianelli N; Sapienza MR; Latagliata R
Br J Haematol; 2018 Oct; 183(1):35-46. PubMed ID: 30010187
[TBL] [Abstract][Full Text] [Related]
4. Addition of navitoclax to ongoing ruxolitinib treatment in patients with myelofibrosis (REFINE): a post-hoc analysis of molecular biomarkers in a phase 2 study.
Pemmaraju N; Garcia JS; Potluri J; Harb JG; Sun Y; Jung P; Qin QQ; Tantravahi SK; Verstovsek S; Harrison C
Lancet Haematol; 2022 Jun; 9(6):e434-e444. PubMed ID: 35576960
[TBL] [Abstract][Full Text] [Related]
5. Correlation of mutation profile and response in patients with myelofibrosis treated with ruxolitinib.
Patel KP; Newberry KJ; Luthra R; Jabbour E; Pierce S; Cortes J; Singh R; Mehrotra M; Routbort MJ; Luthra M; Manshouri T; Santos FP; Kantarjian H; Verstovsek S
Blood; 2015 Aug; 126(6):790-7. PubMed ID: 26124496
[TBL] [Abstract][Full Text] [Related]
6. Epidemiology and clinical relevance of mutations in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 359 patients of the AGIMM group.
Rotunno G; Pacilli A; Artusi V; Rumi E; Maffioli M; Delaini F; Brogi G; Fanelli T; Pancrazzi A; Pietra D; Bernardis I; Belotti C; Pieri L; Sant'Antonio E; Salmoiraghi S; Cilloni D; Rambaldi A; Passamonti F; Barbui T; Manfredini R; Cazzola M; Tagliafico E; Vannucchi AM; Guglielmelli P
Am J Hematol; 2016 Jul; 91(7):681-6. PubMed ID: 27037840
[TBL] [Abstract][Full Text] [Related]
7. Impact of mutational status on outcomes in myelofibrosis patients treated with ruxolitinib in the COMFORT-II study.
Guglielmelli P; Biamonte F; Rotunno G; Artusi V; Artuso L; Bernardis I; Tenedini E; Pieri L; Paoli C; Mannarelli C; Fjerza R; Rumi E; Stalbovskaya V; Squires M; Cazzola M; Manfredini R; Harrison C; Tagliafico E; Vannucchi AM; ;
Blood; 2014 Apr; 123(14):2157-60. PubMed ID: 24458439
[TBL] [Abstract][Full Text] [Related]
8. Ruxolitinib Rechallenge Can Improve Constitutional Symptoms and Splenomegaly in Patients With Myelofibrosis: A Case Series.
Gerds A; Su D; Martynova A; Pannell B; Mukherjee S; O'Neill C; Sekeres M; O'Connell C
Clin Lymphoma Myeloma Leuk; 2018 Nov; 18(11):e463-e468. PubMed ID: 30115545
[TBL] [Abstract][Full Text] [Related]
9. Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study.
Harrison CN; Schaap N; Vannucchi AM; Kiladjian JJ; Tiu RV; Zachee P; Jourdan E; Winton E; Silver RT; Schouten HC; Passamonti F; Zweegman S; Talpaz M; Lager J; Shun Z; Mesa RA
Lancet Haematol; 2017 Jul; 4(7):e317-e324. PubMed ID: 28602585
[TBL] [Abstract][Full Text] [Related]
10. Impact of genomic alterations on outcomes in myelofibrosis patients undergoing JAK1/2 inhibitor therapy.
Spiegel JY; McNamara C; Kennedy JA; Panzarella T; Arruda A; Stockley T; Sukhai M; Thomas M; Bartoszko J; Ho J; Siddiq N; Maze D; Schimmer A; Schuh A; Sibai H; Yee K; Claudio J; Devlin R; Minden MD; Kamel-Reid S; Gupta V
Blood Adv; 2017 Sep; 1(20):1729-1738. PubMed ID: 29296819
[TBL] [Abstract][Full Text] [Related]
11. Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinib.
Bryan JC; Verstovsek S
Cancer Chemother Pharmacol; 2016 Jun; 77(6):1125-42. PubMed ID: 27017614
[TBL] [Abstract][Full Text] [Related]
12. A phase Ib study to assess the efficacy and safety of vismodegib in combination with ruxolitinib in patients with intermediate- or high-risk myelofibrosis.
Couban S; Benevolo G; Donnellan W; Cultrera J; Koschmieder S; Verstovsek S; Hooper G; Hertig C; Tandon M; Dimier N; Malhi V; Passamonti F
J Hematol Oncol; 2018 Sep; 11(1):122. PubMed ID: 30249277
[TBL] [Abstract][Full Text] [Related]
13. Mutation landscape in patients with myelofibrosis receiving ruxolitinib or hydroxyurea.
Pacilli A; Rotunno G; Mannarelli C; Fanelli T; Pancrazzi A; Contini E; Mannelli F; Gesullo F; Bartalucci N; Fattori GC; Paoli C; Vannucchi AM; Guglielmelli P
Blood Cancer J; 2018 Nov; 8(12):122. PubMed ID: 30467377
[TBL] [Abstract][Full Text] [Related]
14. A 10-year retrospective cohort study of ruxolitinib and association with nonmelanoma skin cancer in patients with polycythemia vera and myelofibrosis.
Lin JQ; Li SQ; Li S; Kiamanesh EF; Aasi SZ; Kwong BY; Su Chang AL
J Am Acad Dermatol; 2022 Feb; 86(2):339-344. PubMed ID: 34648874
[TBL] [Abstract][Full Text] [Related]
15. Phase III MANIFEST-2: pelabresib + ruxolitinib vs placebo + ruxolitinib in JAK inhibitor treatment-naive myelofibrosis.
Harrison CN; Gupta VK; Gerds AT; Rampal R; Verstovsek S; Talpaz M; Kiladjian JJ; Mesa R; Kuykendall AT; Vannucchi AM; Palandri F; Grosicki S; Devos T; Jourdan E; Wondergem MJ; Al-Ali HK; Buxhofer-Ausch V; Alvarez-Larrán A; Patriarca A; Kremyanskaya M; Mead AJ; Akhani S; Sheikine Y; Colak G; Mascarenhas J
Future Oncol; 2022 Sep; 18(27):2987-2997. PubMed ID: 35950489
[TBL] [Abstract][Full Text] [Related]
16. Prognostic impact of RAS-pathway mutations in patients with myelofibrosis.
Santos FPS; Getta B; Masarova L; Famulare C; Schulman J; Datoguia TS; Puga RD; Alves Paiva RM; Arcila ME; Hamerschlak N; Kantarjian HM; Levine RL; Campregher PV; Rampal RK; Verstovsek S
Leukemia; 2020 Mar; 34(3):799-810. PubMed ID: 31628430
[TBL] [Abstract][Full Text] [Related]
17. Long-term effects of ruxolitinib versus best available therapy on bone marrow fibrosis in patients with myelofibrosis.
Kvasnicka HM; Thiele J; Bueso-Ramos CE; Sun W; Cortes J; Kantarjian HM; Verstovsek S
J Hematol Oncol; 2018 Mar; 11(1):42. PubMed ID: 29544547
[TBL] [Abstract][Full Text] [Related]
18. Primary myelofibrosis: 2023 update on diagnosis, risk-stratification, and management.
Tefferi A
Am J Hematol; 2023 May; 98(5):801-821. PubMed ID: 36680511
[TBL] [Abstract][Full Text] [Related]
19. The Amelioration of Myelofibrosis with Thrombocytopenia by a JAK1/2 Inhibitor, Ruxolitinib, in a Post-polycythemia Vera Myelofibrosis Patient with a JAK2 Exon 12 Mutation.
Ikeda K; Ueda K; Sano T; Ogawa K; Ikezoe T; Hashimoto Y; Morishita S; Komatsu N; Ohto H; Takeishi Y
Intern Med; 2017; 56(13):1705-1710. PubMed ID: 28674362
[TBL] [Abstract][Full Text] [Related]
20. EZH2 mutational status predicts poor survival in myelofibrosis.
Guglielmelli P; Biamonte F; Score J; Hidalgo-Curtis C; Cervantes F; Maffioli M; Fanelli T; Ernst T; Winkelman N; Jones AV; Zoi K; Reiter A; Duncombe A; Villani L; Bosi A; Barosi G; Cross NC; Vannucchi AM
Blood; 2011 Nov; 118(19):5227-34. PubMed ID: 21921040
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
